Retatrutide Reconstitution Guide: The Triple Agonist Explained

Retatrutide is the newest entrant in the incretin-based peptide research space, and it’s generating serious attention for a simple reason: it targets three receptors instead of the one or two that existing compounds hit. As a triple agonist of GLP-1, GIP, and glucagon receptors, retatrutide represents a genuinely novel mechanism that goes beyond what semaglutide (GLP-1 only) or tirzepatide (GLP-1 + GIP) can offer.

This guide covers what we currently know about reconstituting and working with lyophilized retatrutide, including dosing information from published clinical trial data. Because retatrutide is newer than its predecessors, some practical details are still being established — we’ll note where the evidence is firm and where it’s still emerging.

Quick Summary

• Peptide type: Triple agonist (GLP-1 / GIP / glucagon receptor)
• Common vial size: 5 mg lyophilized powder (typical research supply)
• Research doses (from trials): 1 mg–12 mg weekly (titrated upward)
• Reconstitute with: Bacteriostatic water
• Storage after reconstitution: 2–8°C, estimated 28–42 days (based on structural similarity to tirzepatide)
• Half-life: ~6 days (supports once-weekly dosing)
• Route: Subcutaneous injection
• Use our Peptide Reconstitution Calculator for instant dosing math

What Is Retatrutide?

Retatrutide (also known as LY3437943 in clinical literature) is a synthetic peptide that acts as a simultaneous agonist of three receptors:

1. GLP-1 receptor — the same target as semaglutide. Involved in insulin secretion, appetite suppression, gastric emptying
2. GIP receptor — the same additional target as tirzepatide. Involved in fat metabolism, adipose tissue function, and complementary appetite signaling
3. Glucagon receptor — the new addition. Glucagon receptor activation stimulates hepatic lipid oxidation, increases energy expenditure, and mobilizes liver glycogen

It’s this third receptor — the glucagon receptor — that makes retatrutide conceptually different from its predecessors. While GLP-1 and GIP agonism primarily reduce energy intake (appetite suppression, slowed gastric emptying), glucagon receptor activation increases energy expenditure. The hypothesis is that combining both intake reduction and expenditure increase could produce additive or synergistic effects.

How Retatrutide Compares to Semaglutide and Tirzepatide

The key distinction: retatrutide adds an energy-expenditure lever (glucagon) on top of the appetite-suppression levers (GLP-1/GIP) that existing compounds already pull. Early trial data has been remarkable — the Phase 2 trial (published in NEJM, 2023) reported mean body weight reductions of up to 24.2% at 48 weeks for the 12 mg dose group.

Important Context: Newer = Less Established

Retatrutide is earlier in its development arc than semaglutide or tirzepatide. As of this writing:

• Phase 2 trial data is published and compelling
• Phase 3 trials are underway but results aren’t yet available
• Long-term safety data is limited compared to semaglutide (which has years of post-market data)
• Reconstitution and stability data specific to lyophilized research-grade retatrutide is less standardized

This doesn’t mean researchers can’t work with it — it means best practices are partly extrapolated from structurally similar compounds rather than fully established for retatrutide specifically.

How Retatrutide Is Supplied

Research-grade retatrutide is typically supplied as lyophilized powder:

• 5 mg per vial — the most common research size
• 10 mg per vial — available from some suppliers

The powder is white to off-white. Store unreconstituted vials at -20°C. Like other fatty acid-modified peptides, retatrutide is designed for stability but should still be handled with standard peptide care.

How to Reconstitute Retatrutide

What You’ll Need

• Retatrutide vial (5 mg example used below)
• Bacteriostatic water
• Insulin syringes (1 mL for reconstitution; 0.5 mL or 0.3 mL for dosing)
• Alcohol swabs

Choosing Your Water Volume

For a 5 mg vial:

Recommended: 1 mL of BAC water into a 5 mg vial. This gives you 5 mg/mL, which keeps dose volumes manageable across the titration range. At higher doses (8–12 mg), you’ll be drawing close to or more than the full vial per injection — consider using 10 mg vials reconstituted with 1 mL for those phases.

Step-by-Step Reconstitution

1. Remove the flip-off cap from the retatrutide vial
2. Swab both stoppers (peptide and BAC water vials) with alcohol
3. Draw 1 mL of BAC water
4. Insert the needle through the stopper, angling toward the glass wall
5. Add water slowly over 30–60 seconds. Direct the stream down the wall, not onto the powder
6. Remove the needle and set the vial flat
7. Swirl gently with circular wrist movements — do not shake
8. Wait 3–5 minutes for complete dissolution
9. Inspect. Solution should be clear and colorless

The reconstitution process is essentially identical to semaglutide or tirzepatide. For the complete technique walkthrough, see our peptide mixing guide.

Retatrutide Dosing: What the Trials Show

Dosing information for retatrutide comes primarily from the Phase 2 clinical trial data. The trial used a titration design with multiple dose cohorts.

Trial-Based Titration Schedule

The 12 mg dose was the highest studied in Phase 2. Phase 3 trials may adjust these ranges based on accumulated data. Not all research protocols will escalate to 12 mg — some use 4 mg or 8 mg as the maintenance dose.

Worked Dosing Example

Setup: 5 mg vial reconstituted with 1 mL bacteriostatic water.

Concentration: 5 mg ÷ 1 mL = 5 mg/mL

• 1 mg dose: 1 ÷ 5 = 0.2 mL = 20 units
• 2 mg dose: 2 ÷ 5 = 0.4 mL = 40 units
• 4 mg dose: 4 ÷ 5 = 0.8 mL = 80 units
• 8 mg dose: would require 1.6 mL → need a larger vial or two vials
• 12 mg dose: would require 2.4 mL → need multiple vials or a 10+ mg vial

Practical implication: A 5 mg vial works well for the 1–4 mg dose range. Once you’re at 8 mg or above, you either need 10 mg vials or must draw from two 5 mg vials per dose. For simplicity, most researchers transition to larger vials at higher titration steps.

For syringe reading guidance, see our insulin syringe units guide.

Storage After Reconstitution

Because retatrutide is structurally similar to tirzepatide (both use fatty acid modifications for albumin binding and share similar molecular architectures), storage guidelines are reasonably extrapolated:

Storage Guidelines

• Reconstituted retatrutide: Refrigerate at 2–8°C
• Estimated stability: 28–42 days (extrapolated from similar compounds; follow supplier-specific guidance when available)
• Never freeze reconstituted solution
• Protect from light
• Unreconstituted powder: -20°C for long-term storage

As stability data specific to lyophilized retatrutide becomes more available, these guidelines may be refined. When in doubt, use the more conservative 28-day window.

For broader storage principles, see our peptide storage guide.

Injection Guidance

Retatrutide is administered via subcutaneous injection, once weekly — consistent with its ~6-day half-life.

• Sites: Abdomen, outer thigh, back of upper arm
• Rotate sites weekly
• Needle gauge: 29–31 gauge insulin syringes
• Same day each week for pharmacokinetic consistency

At higher doses (8–12 mg), injection volumes may be large depending on reconstitution concentration. Minimizing water volume helps keep injections comfortable. For technique guidance, see our subcutaneous injection guide.

The Glucagon Component: Why It Matters

The glucagon receptor agonism in retatrutide deserves special attention because it’s the feature that distinguishes it from all other incretin peptides.

What glucagon receptor activation does:

• Increases hepatic lipid oxidation — the liver burns more fat for energy
• Raises energy expenditure — measurable increases in resting metabolic rate
• Mobilizes liver glycogen — breaks down stored glycogen into glucose
• Promotes thermogenesis — increased heat production from metabolism

The concern with glucagon agonism is the glycogenolytic and gluconeogenic effects — glucagon raises blood glucose. In retatrutide, the simultaneous GLP-1 agonism (which lowers blood glucose via insulin stimulation) appears to counterbalance this. The Phase 2 trial data showed improved glycemic control in diabetic participants despite the glucagon component, suggesting the balance favors glucose-lowering overall.

This is a key area of ongoing research. The interplay between three receptor systems creates complex pharmacology that isn’t fully characterized yet.

Practical Tips for Retatrutide Research

Stay current with the literature. Retatrutide is actively being studied. Phase 3 trial results, when published, may change optimal dosing and titration recommendations. Check PubMed and ClinicalTrials.gov periodically.

Start conservatively. The triple agonist mechanism introduces variables that single and dual agonists don’t have. The 1 mg starting dose is lower relative to the maximum dose (1:12 ratio) compared to semaglutide (0.25:2.4, roughly 1:10) or tirzepatide (2.5:15, 1:6).

Plan vial procurement for dose escalation. The wide dose range (1–12 mg) means you’ll likely need different vial sizes at different phases. Don’t buy 20 vials of 5 mg at the start if you’ll need 10 mg vials by month 3.

Expect GI effects during titration. Like all GLP-1-containing agonists, nausea is common during dose escalation. The titration schedule is designed to minimize this.

Calculate Your Exact Dose

Retatrutide’s wide dose range and multiple vial size options make manual math tedious. Let our calculator do the heavy lifting.

Try our free Peptide Reconstitution Calculator to calculate your exact retatrutide dosing.

This content is for educational and research purposes only. Retatrutide is an investigational compound currently in clinical trials. Always follow applicable regulations and consult with qualified professionals regarding research protocols.